How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil
Authors:
- Luisa Couceiro de Albuquerque MacêdoLMLuisa Couceiro de Albuquerque Macêdo
- Raphaelly Ribeiro CamposRCRaphaelly Ribeiro Campos
- Luiz Eduardo Duarte Borges NunesLNLuiz Eduardo Duarte Borges Nunes
- Mariana Gonçalves Maciel PinheiroMPMariana Gonçalves Maciel Pinheiro
- Alberto Henrique Torres Trindade da SilvaASAlberto Henrique Torres Trindade da Silva
- Maria Regina Vendas Carneiro LeãoMLMaria Regina Vendas Carneiro Leão
- Aldson dos Santos SilvaASAldson dos Santos Silva
- Felipe Alves MouratoFMFelipe Alves Mourato
- Simone Cristina Soares BrandãoSBSimone Cristina Soares Brandão
- Breno José Alencar Pires BarbosaBBBreno José Alencar Pires Barbosa
Open Access
- 9 May 2025
- journal article
- research article
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (05) , 001-008
Abstract
Since the advent of 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG, henceforth, FDG) in the 1970s as a neurochemical tracer, FDG positron emission tomography (PET) has been used for research in dementia and to help diagnose dementing neurodegenerative disorders. However, FDG PET is still unavailable in most centers, especially those in low- and middle-income countries, and there is limited data on biomarkers from patients in diverse populations, such Latin Americans.To analyze the main indications and how the use of FDG PET helped improve the diagnosis of dementia in a specialized center in Recife, one of the largest cities in Northeastern Brazil.We retrospectively analyzed data from 62 individuals under follow-up at our center between 2018 and 2023 who had a clinical diagnosis of dementia or mild cognitive impairment and underwent FDG PET scans.In 21/29 (72.4%) patients, FDG PET helped investigate the types of atypical neurodegenerative dementias; in 14/24 (58.3%), it clarified the clinical question in the investigation of early-onset dementia syndromes; and, in 9 cases, it was performed to differentiate between degenerative and non-degenerative dementias.These numbers may set the foundation for further longitudinal analyses and collaborative studies including participants from Northeastern Brazil.Keywords
This publication has 27 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- A call for clinical trial globalization in Alzheimer's disease and related dementiaAlzheimer's & Dementia, 2023
- Risk factors for dementia in Brazil: Differences by region and raceAlzheimer's & Dementia, 2022
- EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3European Journal of Nuclear Medicine and Molecular Imaging, 2021
- Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing DisordersSeminars in Nuclear Medicine, 2021
- FDG‐PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal SyndromeMovement Disorders, 2020
- Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementiasThe Lancet Neurology, 2020
- Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Impact of molecular imaging on the diagnostic process in a memory clinicAlzheimer's & Dementia, 2012